Contact Marin & Murphy

Marin & Murphy is licensed in South Carolina, Massachusetts, Rhode Island, and Connecticut, and works with lawyers licensed across the country.

Marin & Murphy is not licensed in California; a matter there would be handled with, or referred to, a lawyer licensed in that state.

Super Lawyers® 2014–2024(888) 348-2735

Dupixent — CTCL Litigation

The Dupixent Litigation, Explained

Federal cases are consolidated in MDL 3180, most cases are in their earliest stages, and no settlement exists. Here is what is publicly known.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · deadlines vary by state.

Marin & Murphy is not licensed in California; details below.

Attorneys Stefanie A. Murphy and Matthew T. Marin of Marin & Murphy Law Firm

Partners

Stefanie A. Murphy & Matthew T. Marin

Super Lawyers® honorees · members of the American Association for Justice · concentrating in personal injury and mass-tort litigation.

No settlement has been reached in the Dupixent litigation, and most cases are in their earliest stages. Every case must be proven on its own facts. Whether any patient has a claim depends on the facts and the law of their state. The information below covers the litigation itself.

Marin & Murphy Law Firm is not licensed in California; details below.

For readers in California the essentials are the same: plaintiffs allege an association between Dupixent (dupilumab) and cutaneous T-cell lymphoma, no court has found Dupixent causes CTCL, and no settlement exists. Whether any individual has a claim depends on their medical records and the law of their state. The information below covers the litigation itself.

The Dupixent CTCL Litigation: Where Things Stand

Made by Sanofi and Regeneron and prescribed in California as it is across the country, Dupixent (dupilumab) is a prescription biologic, FDA-approved since March 2017, now carrying nine indications, including atopic dermatitis, asthma, and COPD. In June 2026 — the date that governs California cases too — the Judicial Panel on Multidistrict Litigation centralized the pending federal cases as MDL 3180 in the United States District Court for the District of New Jersey, before Judge Zahid N. Quraishi. The complaints in the consolidated Dupixent lawsuit allege that the drug is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn patients and doctors. As of November 2, 2026, 40 cases were pending in the MDL that would govern any filing from California; the current count and its method are kept on the MDL 3180 tracker. No merits ruling exists anywhere, California included, and neither does any settlement.

The Allegations — and Their Limits

For readers in California: what is alleged is an association, and nothing has been adjudicated. Published studies report a statistical association between dupilumab and CTCL — an association the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal for CTCL that it is still evaluating. No lymphoma or malignancy warning appears on Dupixent’s current label, in California or anywhere else. The FDA adverse event reports connected to this question are agency reports, not verified causes, and the courts have decided nothing on the merits — in California or anywhere else.

California Residents in the Dupixent MDL: Four Docketed Cases

A California resident filed Bell v. Regeneron Pharmaceuticals, Inc. in the Eastern District of California on February 5, 2026 (No. 2:26-cv-00320, public docket), alleging Dupixent injections from July 2019 to about June 2020 and a diagnosis of cutaneous T-cell lymphoma in approximately November 2021; the complaint names Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC and includes a spouse’s loss-of-consortium claim. Three additional California-resident cases are on the same track: Mun (Southern District of California, January 2026), Bundy (Central District of California, February 2026, pleading anaplastic large cell lymphoma as a CTCL subtype), and Perez, filed directly in the District of New Jersey in August 2026 against Sanofi-Aventis U.S. LLC, Regeneron, and Genzyme Corporation. All four proceed in MDL 3180. These are allegations from a complaint; no court has ruled on them, and no settlement exists.

Who Falls Within the Filed Cases?

The consolidated cases — whether from California or elsewhere — involve people who used Dupixent and were diagnosed with cutaneous T-cell lymphoma or a related T-cell lymphoma subtype during or after that use. The claims carry no minimum-use requirement, and in California, estates of patients who have died may bring claims under state wrongful-death and survival statutes. Whether any individual’s circumstances resemble the filed cases is a question of medical records and state law, not of headlines — and for a California resident, it is a question for an attorney licensed in California.

California’s Federal Courts and the Path to MDL 3180

California is served by four federal district courts: the United States District Court for the Northern District of California; the United States District Court for the Eastern District of California; the United States District Court for the Central District of California; and the United States District Court for the Southern District of California. A Dupixent CTCL lawsuit filed there does not proceed alone: the Judicial Panel on Multidistrict Litigation has centralized these cases as MDL 3180 before Judge Zahid N. Quraishi in the United States District Court for the District of New Jersey, so a California case is transferred to the MDL for coordinated pretrial proceedings — or, where the MDL court’s case-management orders permit, filed in the District of New Jersey directly. Either route leads to the same consolidated proceeding, and a case from California remains an individual claim; an MDL is not a class action.

Filing Deadlines Under California Law

California’s general statute of limitations for personal-injury claims is two years under Cal. Code Civ. Proc. § 335.1. California applies a discovery rule: a claim accrues when the plaintiff is on inquiry notice of the cause of action. How a limitations period applies to any specific CTCL diagnosis depends on the dates in the medical records, the legal theory pleaded, and California tolling and accrual doctrine. An attorney licensed in California can evaluate whether a claim is timely.

A wrongful-death claim carries a two-year period that begins at death (Cal. Code Civ. Proc. § 335.1), brought by the personal representative.

How Common Is CTCL in California?

California is home to about 39.4 million people (U.S. Census Bureau, 2024 estimate). Cutaneous T-cell lymphoma is rare — roughly 8.55 new cases per million person-years (SEER) — which works out to on the order of 340 new CTCL diagnoses across California in a typical year. Rarity means the numbers on this page cannot answer an individual question — in California, any one claim is decided by medical records read against state law.

About Marin & Murphy Law Firm and California

Marin & Murphy Law Firm is a personal-injury and mass-tort law firm; its attorneys’ individual admissions are listed at the bottom of this page, and this page is published as litigation information. Marin & Murphy Law Firm is not licensed in California. The firm does not accept California legal matters; inquiries from California residents are referred to attorneys licensed in California. Some matters may be referred to other lawyers. An attorney licensed in California can evaluate whether a claim is timely and how California law applies to a particular diagnosis.

California Dupixent Litigation FAQs

Are there Dupixent lawsuits in California courts?

Rather than proceeding separately around the country, the federal cases — filings from California included — are consolidated in MDL 3180 in the District of New Jersey. A Dupixent CTCL case filed in a California federal court is subject to transfer into that consolidated proceeding. This page does not track filings outside the federal system.

Who is included in the filed cases?

People — from California or anywhere — who used Dupixent and were diagnosed with cutaneous T-cell lymphoma or a related T-cell lymphoma subtype during or after that use. There is no minimum-use requirement, and estates of patients who have died — in California as elsewhere — bring claims under state wrongful-death and survival statutes.

Has any court found that Dupixent causes CTCL?

No. Plaintiffs allege an association; published studies report a statistical association that their authors note does not establish causation; the FDA is still evaluating a potential safety signal; and the Dupixent label — the same one dispensed in California — currently contains no lymphoma warning.

Is there a Dupixent settlement?

No. No settlement exists and no court has ruled on the merits — the litigation, claims from California included, is in its earliest stages. A number implying otherwise, wherever a reader in California saw it, did not come from the docket.

What is the filing deadline for a California Dupixent claim?

Filing deadlines come from California statutes and court doctrine, and more than one rule can bear on when the period begins to run; the section above covers what is settled and what is not. An attorney licensed in California can evaluate whether a claim is timely.

Does Marin & Murphy Law Firm accept California cases?

No. Marin & Murphy Law Firm is not licensed in California and does not accept California legal matters; inquiries from California residents are referred to attorneys licensed in California.

California Dupixent Prescribing: The Publicly Reported Numbers

Atopic dermatitis and other inflammatory conditions make Dupixent (dupilumab) a frequently prescribed medication in California. Federal drug-utilization data shows how often it is dispensed:

79,105Dupixent prescriptions reported by Medicaid in California in 2025
59,472Dupixent prescriptions reported by Medicaid in California in 2024
3Schedule A actions in MDL 3180 were filed in California federal courts before transfer

Reported Medicaid prescriptions in California rose about 33% from 2024 to 2025. California’s Medicaid program reported $317.6 million in total Dupixent reimbursement in 2025. Because these figures capture only Medicaid outpatient utilization — not Medicare or private-insurance prescriptions — the full count of residents of California using Dupixent is higher. The totals also omit a small number of records suppressed for privacy.

3 of the 15 actions on Schedule A of the transfer order were filed in California federal courts before the Judicial Panel on Multidistrict Litigation centralized the Dupixent lawsuits into MDL 3180 in the District of New Jersey on June 4, 2026.

Sources: Centers for Medicare & Medicaid Services, State Drug Utilization Data 2024 and 2025 (accessed August 21, 2026); In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, JPML Transfer Order, Schedule A (June 4, 2026). Utilization data reflects prescriptions reported by state Medicaid programs and is not evidence that any individual prescription caused injury.

Sources
  • U.S. Judicial Panel on Multidistrict Litigation, Pending MDL Dockets by MDL Number (November 2, 2026) — jpml.uscourts.gov
  • MDL 3180 docket records — CourtListener dockets 72288297 (JPML) and 73443394 (D.N.J. 3:26-md-03180), reviewed September 15, 2026.
  • Cal. Code Civ. Proc. § 335.1 — California statute of limitations discussed above.
  • U.S. Census Bureau, Vintage 2024 Population Estimates (NST-EST2024), resident population as of July 1, 2024.
  • SEER program data: cutaneous T-cell lymphoma incidence ≈8.55 cases per million person-years.

Where we practice

Marin & Murphy Law Firm is a national mass tort and personal injury law firm with offices in Rhode Island, Connecticut and South Carolina, representing injured people and families nationwide. Where a matter arises in a state in which our attorneys are not admitted, we work with lawyers licensed in that state. We are not licensed in California. The firm does not accept California legal matters; inquiries from California residents are referred to attorneys licensed in California. This page is attorney advertising and is provided for general information; it is not legal advice, and reading it does not create an attorney–client relationship.